Not a subscriber ?  Start your complimentary Premium trial now
 

CSL Limited (CSL) Articles

 
News Articles: top ^

Is this the beginning of a corrective phase?

Author: Lesley Beath
Date: 12 Sep 2016

The US market finally awoke from its slumber last Friday

Brambles' profit meets guidance, CEO retires

Author: Nicholas Grove
Date: 18 Aug 2016

Brambles Limited (ASX: BXB) on Thursday announced an underlying profit of US$623.1 million for fiscal 2016, up 8 per cent on the prior year in constant currency terms, and underlying earnings per share (EPS) of 39.5 US cents, up 7 per cent

CSL shares lower but not for long

Author: Nicki Bourlioufas
Date: 17 Aug 2016

Shares in Australian biopharmaceutical company CSL Limited (ASX: CSL) have dropped after the company posted a 10 per cent fall in full-year net profit to US$1.24 billion ($1.6 billion), dragged down by the company's purchase of the loss-making influenza vaccine business Novartis

CSL celebrates anniversary with record profit

Author: Anthony Fensom
Date: 17 Feb 2016

Blood products maker CSL Limited (CSL) has celebrated its 100th anniversary by posting a record US$719 million net profit, up 4 per cent on the previous half year, with double-digit sales growth across its plasma therapy units

Lift from lower dollar not that great

Author: Nicki Bourlioufas
Date: 11 Dec 2015

The fall in the Australian dollar will only give a moderate lift to several companies in 2016, given many have revenue in sterling or euros and any further decline in the Australian dollar could be limited by meaningful offshore investment and merger and acquisitions activity, according to Morningstar head of equities research Peter Warnes

CSL, Stockland and AGL grow earnings

Author: Nicholas Grove
Date: 11 Feb 2015

Companies covered in this report: • CSL Limited (CSL)

CSL, Primary Health Care lift profits

Author: Nicholas Grove
Date: 13 Aug 2014

Companies covered in this report: • CSL Limited

CSL and Primary reaffirm guidance

Author: Nicholas Grove
Date: 12 Feb 2014

Companies covered in this report: • CSL Limited

3 top no-moat healthcare plays

Author: Nicholas Grove
Date: 23 Oct 2013

While the positive attributes and competitive advantages of Australian narrow-moat healthcare giants CSL Limited (CSL) and Cochlear Limited (COH) will be well-known to Morningstar readers, it's easy to forget there are other companies within the sector that may add value to certain portfolios


Advantages of Premium Membership

Your Money Weekly Newsletter

Independent stocks newsletter has been aiding Australian investors for over 30 years.

Independent Fund Analyst Research

For the first time in Australia Morningstar Qualitative Fund Research is directly available to individual investors.

Portfolio X-Ray

Ensure your portfolio is positioned exactly how you want with Morningstar's Portfolio X-Ray. You can discover how much of a stock you really own, individually and through managed funds with Stock Intersection.

Investment Picks

Find greatly undervalued stocks to consider daily. Browse our Fund Analyst Picks to find managed funds that best suit your needs.

Access these features and more when you sign up for Premium Membership.